Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc. - Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI®(taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Inc. - Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI®(taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak clinical signals • Minimal impact anticipated **Sentiment:** Neutral (50%) **Content type:** Clinical